TR201902981T4 - N-(4-kloro-2-hidroksi-3-((3s)-3-piperidinilsülfonil)fenil)-n'-(3-floro-2-metilfenil)ürenin hidrobromür tuzu. - Google Patents

N-(4-kloro-2-hidroksi-3-((3s)-3-piperidinilsülfonil)fenil)-n'-(3-floro-2-metilfenil)ürenin hidrobromür tuzu. Download PDF

Info

Publication number
TR201902981T4
TR201902981T4 TR2019/02981T TR201902981T TR201902981T4 TR 201902981 T4 TR201902981 T4 TR 201902981T4 TR 2019/02981 T TR2019/02981 T TR 2019/02981T TR 201902981 T TR201902981 T TR 201902981T TR 201902981 T4 TR201902981 T4 TR 201902981T4
Authority
TR
Turkey
Prior art keywords
piperidinylsulfonyl
methylphenyl
fluoro
chloro
urea
Prior art date
Application number
TR2019/02981T
Other languages
English (en)
Inventor
Dominic Sanderson Francis
Mary Vallance Sarah
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of TR201902981T4 publication Critical patent/TR201902981T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

N-{4-kloro-2-hidroksi-3-[(3S)-3-piperidinilsülfonil]fenil}-N'-(3-floro-2-metilfenil)ürenin hidrobromür tuzu olan bir bileşik, adı geçen bileşikleri içeren bileşimler, kombinasyonlar ve ilaçlar ve bunları hazırlama işlemleri açıklanmıştır. Buluş aynı zamanda adı geçen kombinasyonları, bileşimlerin ve ilaçların kullanımı ile ilgilidir.
TR2019/02981T 2013-11-13 2014-11-11 N-(4-kloro-2-hidroksi-3-((3s)-3-piperidinilsülfonil)fenil)-n'-(3-floro-2-metilfenil)ürenin hidrobromür tuzu. TR201902981T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds

Publications (1)

Publication Number Publication Date
TR201902981T4 true TR201902981T4 (tr) 2019-03-21

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/02981T TR201902981T4 (tr) 2013-11-13 2014-11-11 N-(4-kloro-2-hidroksi-3-((3s)-3-piperidinilsülfonil)fenil)-n'-(3-floro-2-metilfenil)ürenin hidrobromür tuzu.

Country Status (23)

Country Link
US (3) US9809540B2 (tr)
EP (1) EP3068763B1 (tr)
JP (1) JP6401265B2 (tr)
KR (1) KR20160083950A (tr)
CN (1) CN105683162A (tr)
AU (1) AU2014350334B2 (tr)
BR (1) BR112016010409A8 (tr)
CA (1) CA2929907A1 (tr)
CY (1) CY1121581T1 (tr)
DK (1) DK3068763T3 (tr)
ES (1) ES2714721T3 (tr)
GB (1) GB201320021D0 (tr)
HR (1) HRP20190449T1 (tr)
HU (1) HUE041873T2 (tr)
LT (1) LT3068763T (tr)
ME (1) ME03328B (tr)
PL (1) PL3068763T3 (tr)
PT (1) PT3068763T (tr)
RS (1) RS58382B1 (tr)
RU (1) RU2685408C1 (tr)
SI (1) SI3068763T1 (tr)
TR (1) TR201902981T4 (tr)
WO (1) WO2015071235A1 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072976A (zh) * 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
EP3383364A1 (en) * 2015-11-30 2018-10-10 Glaxosmithkline Intellectual Property (No. 2) Limited Formulations for intravenous injection of danirixin
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI414517B (zh) * 2006-04-21 2013-11-11 Smithkline Beecham Corp Ｉｌ-８受體拮抗劑

Also Published As

Publication number Publication date
HUE041873T2 (hu) 2019-05-28
PL3068763T3 (pl) 2019-05-31
KR20160083950A (ko) 2016-07-12
JP6401265B2 (ja) 2018-10-10
US20180079722A1 (en) 2018-03-22
PT3068763T (pt) 2019-03-20
HRP20190449T1 (hr) 2019-04-19
US10604485B2 (en) 2020-03-31
DK3068763T3 (en) 2019-03-18
GB201320021D0 (en) 2013-12-25
SI3068763T1 (sl) 2019-04-30
AU2014350334B2 (en) 2017-08-10
AU2014350334A1 (en) 2016-06-02
BR112016010409A8 (pt) 2020-04-22
LT3068763T (lt) 2019-03-12
JP2016537344A (ja) 2016-12-01
CA2929907A1 (en) 2015-05-21
CY1121581T1 (el) 2020-05-29
US9809540B2 (en) 2017-11-07
EP3068763A1 (en) 2016-09-21
RU2685408C1 (ru) 2019-04-18
RU2016116955A (ru) 2017-12-19
EP3068763B1 (en) 2018-12-19
WO2015071235A1 (en) 2015-05-21
US20160264525A1 (en) 2016-09-15
ES2714721T3 (es) 2019-05-29
RS58382B1 (sr) 2019-04-30
US20190112269A1 (en) 2019-04-18
ME03328B (me) 2019-10-20
CN105683162A (zh) 2016-06-15

Similar Documents

Publication Publication Date Title
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
EA201600366A1 (ru) Производные бензимидазол-пролина
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
EA201691119A1 (ru) Производные мочевины или их фармакологически приемлемые соли
EA201591756A1 (ru) Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
TR201902435T4 (tr) DGAT1 inhibitör içeren farmasötik bileşimler.
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
TR201902057T4 (tr) Tetrasiklin bileşikleri.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
TN2014000497A1 (en) Carbamate/urea derivatives
EA200901389A1 (ru) Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы
CY1121581T1 (el) Υδροβρωμικο αλας n-(4-xλωpo-2-yδpoξy-3-((3s)-3-πιπεριδινυλσουλφονυλ)φαινυλ)-ν'-(3-φθορο-2-μεθυλφαινυλ)ουριας
EA201000340A1 (ru) Аминобензилзамещенные циклические сульфоны, полезные в качестве ингибиторов васе
EA201600323A1 (ru) Производные пиперазина и их применение в качестве лекарственного средства
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2